Orchid Pharma Ltd
Pharmaceuticals & Biotechnology | Small Cap
Orchid Pharma Ltd demonstrates a mixed financial performance. The company shows some strength in solvency, driven by a solid equity position. Growth is fueled by operating profit and asset increases. Profitability is supported by a good return on capital employed and return on assets. However, liquidity is a significant concern due to poor current, quick, and cash ratios. Efficiency is also a trouble area, as key turnover ratios are low. Financial ratios are hindered by low earnings per share and book value. While coverage is reasonable, it is mainly due to interest coverage rather than equity dividend coverage. The company needs to address its liquidity and efficiency challenges to ensure long-term sustainability and growth.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio4.00
- Financial Ratio4.00
- Profitability Ratio4.40
- Efficiency Ratio4.67
- Coverage Ratio6.80
- Solvency Ratio10.00
- Liquidity Ratio2.00
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursBearish
- 4 HoursNeutral
- 1 DayBullish
- 1 WeekBullish
- 1 MonthNeutral
Orchid Pharma Ltd demonstrates a mixed financial performance. The company shows some strength in solvency, driven by a solid equity position. Growth is fueled by operating profit and asset increases. Profitability is supported by a good return on capital employed and return on assets. However, liquidity is a significant concern due to poor current, quick, and cash ratios. Efficiency is also a trouble area, as key turnover ratios are low. Financial ratios are hindered by low earnings per share and book value. While coverage is reasonable, it is mainly due to interest coverage rather than equity dividend coverage. The company needs to address its liquidity and efficiency challenges to ensure long-term sustainability and growth.
Overall Valuation Score
P/E RATIO (TTM)
109.88
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
241.74
P/B RATIO
3.85
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
5.70
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
0.00
EV/EBITDA RATIO
70.60
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹979.05 as on Jun 19, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company shows good operating profit and asset growth. However, revenue and net income growth are not doing good. The weighted average calculation shows that while some areas are growing, others are lagging. The company needs to focus on driving revenue and net income growth to achieve more balanced and sustainable growth.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 24.44 | 18.93 | 22.97 | 12.58 | -12.04 |
| Operating Profit Growth Rate | 89.66 | 52.73 | 32.14 | 6.31 | -65.25 |
| Earnings Per Share (EPS) Growth | -98.32 | -2464.58 | 60.09 | 8.15 | -79.39 |
| Asset Growth Rate | -10.19 | 10.26 | 26.86 | 8.62 | 13.21 |
| Net Income Growth Rate | -98.29 | -2400 | 100 | 8.7 | -79 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The financial ratios present a mixed view. Cash earnings per share is a strength, but adjusted earnings per share, book value per share, and dividend per share are low. The weighted average calculation reflects these mixed results. The company should focus on improving its earnings and book value to enhance its financial position. The company's capital expenditures are low which is not good for long-term.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | -0.73 | 1.46 | 18.04 | 19.61 | 5.49 |
| Cash Earnings Per Share (Cash EPS) | 20.73 | 24.63 | 24.51 | 26.47 | 10.98 |
| Book Value Per Share | 158.05 | 168.05 | 229.41 | 248.63 | 252.55 |
| Dividend Per Share (DPS) | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures (CapEx) | 146 | 26 | 65 | 150 | 375 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability is mixed. Return on capital employed and return on assets are strengths, but gross profit margin, return on equity, operating margin, and net margin are low. The weighted average calculation highlights the need to improve overall profitability. The company should focus on increasing its margins and returns to achieve better financial performance.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | -5.71 | 4.35 | 9.52 | 9 | 0.74 |
| Return on Capital Employed (ROCE) | -2 | 5 | 9 | 8 | 3 |
| Return on Equity (ROE) | -0.31 | 6.68 | 7.86 | 7.89 | 1.63 |
| Return on Assets (ROA) | 4.95 | 6.86 | 7.14 | 6.99 | 2.15 |
| Operating Margin | 9.82 | 12.61 | 13.55 | 12.8 | 5.06 |
| Net Margin | -0.36 | 6.91 | 11.23 | 10.85 | 2.59 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The efficiency ratios show a mixed picture. While days sales in inventory and receivable days are managed well, the turnover ratios for fixed assets, inventory, receivables, and capital are low. The weighted average calculation highlights the need to improve asset utilization. The company should focus on optimizing its operations to enhance efficiency and improve overall asset turnover. This could lead to better profitability and return on investment.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 0.96 | 1.16 | 1.32 | 1.46 | 1.17 |
| Inventory Turnover Ratio | 3.63 | 3.16 | 3.01 | 2.84 | 2.77 |
| Receivables Turnover Ratio | 3.65 | 3.45 | 3.99 | 4.21 | 3.21 |
| Days Sales in Inventory Ratio | 100.55 | 115.51 | 121.26 | 128.52 | 131.77 |
| Receivable Days | 100 | 105.8 | 91.48 | 86.7 | 113.71 |
| Capital Turnover Ratio | 0.65 | 0.79 | 0.63 | 0.66 | 0.5 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's coverage ratios are supported by a strong interest coverage ratio. The weighted average calculation shows a reasonable ability to cover interest expenses, but no ability to cover equity dividend payments. This suggests that while the company can manage its debt obligations, it is not in a position to provide returns to equity holders through dividends.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 1.06 | 2.45 | 6.41 | 7.4 | 2.62 |
| Equity Dividend Coverage Ratio |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company's solvency is strong, with a very strong equity position. The weighted average calculation, gives a positive view of the company's long-term financial stability. This suggests that the company has a low level of debt relative to its assets. The company's equity position provides a solid foundation for future growth and stability.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.24 | 0.18 | 0.09 | 0.09 | 0.21 |
| Debt to Equity Ratio | 0.32 | 0.22 | 0.1 | 0.1 | 0.27 |
| Equity Ratio | 0.76 | 0.82 | 0.91 | 0.91 | 0.79 |
| Debt To Asset Ratio | 0.19 | 0.12 | 0.08 | 0.08 | 0.17 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position is weak, indicating potential difficulties in meeting short-term obligations. The weighted average calculation, which emphasizes recent performance, reveals consistently low ratios. This might be because the company is unable to efficiently convert its current assets into cash. This situation needs immediate attention to avoid any financial distress.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.85 | 1.45 | 3.26 | 3.2 | 2.84 |
| Quick Ratio | 1.17 | 0.86 | 2.25 | 2.07 | 1.96 |
| Cash Ratio | 0.03 | 0.08 | 1.02 | 0.62 | 0.29 |
| Operating Cash Flow Ratio | 0.36 | 0.05 | 0.48 | 0.07 | 0.35 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Amrutanjan Health Care Ltd | 8.25 | 77.37 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 2 | Supriya Lifescience Ltd | 7.46 | 35.88 | Highly Overvalued | 294.00 | 25.98 | 209.00 |
| 3 | Aarti Pharmalabs Ltd | 7.46 | 35.90 | Neutral | 369.00 | 19.44 | 175.00 |
| 4 | Innova Captab Ltd | 7.36 | 38.55 | Overvalued | 243.00 | 14.63 | 141.00 |
| 5 | Akums Drugs & Pharmaceuticals Ltd | 7.28 | 37.30 | Overvalued | 522.00 | 7.09 | 256.00 |
| 6 | Hikal Ltd | 7.13 | -51.71 | Neutral | 220.00 | -3.95 | -49.00 |
| 7 | RPG Life Sciences Ltd | 7.12 | 32.70 | Neutral | 147.00 | 69.64 | 115.00 |
| 8 | Morepen Laboratories Ltd | 7.12 | 28.61 | Neutral | 126.00 | 1.21 | 96.00 |
| 9 | Alembic Ltd | 7.06 | 7.28 | Undervalued | 90.00 | 4.85 | 317.00 |
| 10 | SMS Pharmaceuticals Ltd | 5.94 | 34.77 | Neutral | 171.00 | 9.35 | 102.00 |
| 11 | Gufic BioSciences Ltd | 5.49 | 55.51 | Neutral | 151.00 | 6.30 | 64.00 |
| 12 | Dishman Carbogen Amcis Ltd | 5.38 | 27.45 | Neutral | 566.00 | -2.45 | 97.00 |
| 13 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 27.76 | Undervalued | 269.00 | 4.69 | 138.00 |
| 14 | Indoco Remedies Ltd | 5.26 | -22.79 | Neutral | 142.00 | -0.61 | -99.00 |
| 15 | Aarti Drugs Ltd | 5.07 | 17.34 | Undervalued | 309.00 | 18.54 | 195.00 |
| 16 | Orchid Pharma Ltd | 4.85 | 241.74 | Neutral | 41.00 | 8.91 | 21.00 |
| 17 | Sequent Scientific Ltd | 4.61 | 293.05 | Overvalued | 162.00 | 0.63 | 32.00 |
| 18 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.97 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 19 | Solara Active Pharma Sciences Ltd | 4.34 | -274.68 | Neutral | 187.00 | -1.50 | -7.00 |
| 20 | Zota Health Care Ltd | 3.97 | -61.25 | Neutral | 19.00 | 8.06 | -74.00 |
Orchid Pharma Ltd's management effectiveness shows potential amidst certain challenges. Sales and profit growth have improved, but a significant decrease in promoter holding and inefficient working capital management are concerning. The company's financial health has been bolstered by substantial debt reduction, but inconsistent profitability remains a point of concern. Overall, the management demonstrates a mixed performance, requiring strategic improvements in key areas.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Sales Growth (3Y) | 18% | Revenue expansion is improving |
| Profit Growth (3Y) | 249% | Profit growth is improving | |
| CONS | Promoter Holding (Mar 2025) | 69.84% | Confidence and alignment with shareholders is weak |
| Cash Conversion Cycle (Mar 2025) | 166 Days | Working capital management is inefficient |
Financial Performance & Growth
Orchid Pharma's financial performance and growth present a mixed scenario. Sales growth shows improvement, with a 3-year compounded growth of 18% and a TTM growth of 13%. Profit growth is robust, with a 3-year compounded growth of 249%. However, the YOY Profit Growth % in the most recent quarter (Mar 2025) declined to -32.37%. OPM % has been relatively stable, around 12-14% in recent quarters. The company's historical performance shows volatility, with periods of losses followed by recent profitability.
| Metric | 2016-2018 | 2019-2021 | 2022-2024 | 2025 |
|---|---|---|---|---|
| Sales CAGR (%) | -8.7% | 13.1% | 16.7% | 13% |
| Profit CAGR (%) | N/A | N/A | N/A | 8% |
Capital Efficiency & Returns
Orchid Pharma's capital efficiency and returns present a mixed picture. The Return on Capital Employed (ROCE) has improved in recent years, reaching 8% in Mar 2025, up from negative values in previous years. Similarly, the Return on Equity (ROE) has also increased. The Cash Conversion Cycle remains high at 166 days as of Mar 2025, indicating inefficiencies in working capital management.
| Metric | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| ROCE (%) | -4.67% | -3% | 5% | 9% | 8% |
Financial Health & Prudence
Orchid Pharma has significantly improved its financial health by reducing its debt. Borrowings have decreased substantially from ₹3,215 Cr in Mar 2016 to ₹175 Cr in Mar 2025. Interest coverage has improved as a result of decreased interest expenses. The company has not been paying dividends, with a Dividend Payout % of 0% consistently.
| Metric | 2016-2018 | 2019-2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Borrowings (Cr) | 3171.67 | 506.33 | 268 | 331 | 135 | 175 |
Shareholding & Ownership Structure
There has been a notable change in the shareholding pattern. Promoter holding has decreased from 89.96% in Mar 2023 to 69.84% in Mar 2025. Institutional holding (FII/DII) has increased, with DIIs showing a more significant increase. FII holding has increased from 0.81% in Mar 2023 to 2.69% in Mar 2025, and DII holding has increased from 2.62% in Mar 2023 to 20.10% in Mar 2025.
| Metric | Mar 2017 | Mar 2019 | Mar 2021 | Mar 2023 | Mar 2025 |
|---|---|---|---|---|---|
| Promoter Holding (%) | 26.68 | 26.68 | 98.07 | 89.96 | 69.84 |
| FII Holding (%) | 1.14 | 0.80 | 0.04 | 0.81 | 2.69 |
| DII Holding (%) | 4.19 | 3.72 | 1.00 | 2.62 | 20.10 |
Orchid Pharma has a moderate risk profile. Debt has been reduced, but operational efficiency is a concern due to the high cash conversion cycle. Volatility in quarterly profit growth and a decrease in promoter holding raise concerns about stability. Financial health has improved, but working capital management and profitability challenges persist.
Foreign exchange or interest rate exposure
The company's operations may be subject to currency fluctuations, especially considering its presence in the healthcare sector. Interest rate exposure is relevant, although borrowings have reduced significantly, potentially lowering the impact of interest rate changes on profitability.
Accounting quality red flags
Based on the provided data, there are no glaring accounting red flags.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
- IndicatorValueSignal
- SMA 10991.48Bearish
- SMA 201009.91Bearish
- SMA 50955.34Bullish
- EMA 10988.18Bearish
- EMA 20991.27Bearish
- EMA 50959.72Bullish
- DEMA 10976.20Bearish
- DEMA 201000.01Bearish
- DEMA 501017.97Bearish
- TEMA 10966.40Bullish
- TEMA 20981.14Bearish
- TEMA 501021.59Bearish
- MACD3.35Bearish
- ADX36.40Strong Trend
- IndicatorValueSignal
- RSI43.27Neutral
- CCI-122.48Oversold
- ROC 9-4.57Bearish
- ROC 14-6.58Bearish
- ROC 255.85Bullish
- Stoch K4.62Oversold
- Stoch D5.08Oversold
- IndicatorValueSignal
- BB Upper1055.74Neutral
- BB Middle1009.90Neutral
- BB Lower964.07Neutral
- ATR20.64High Volatility
- IndicatorValueSignal
- MFI8.17Oversold
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 101004.36Bearish
- SMA 20992.17Bearish
- SMA 50911.06Bullish
- EMA 10990.62Bearish
- EMA 20978.27Bearish
- EMA 50920.14Bullish
- DEMA 10990.03Bearish
- DEMA 201014.29Bearish
- DEMA 501006.03Bearish
- TEMA 10971.83Bearish
- TEMA 201004.80Bearish
- TEMA 501023.55Bearish
- MACD23.63Bearish
- ADX52.67Strong Trend
- IndicatorValueSignal
- RSI51.69Neutral
- CCI-37.70Neutral
- ROC 9-6.02Bearish
- ROC 147.20Bullish
- ROC 2514.55Bullish
- Stoch K38.81Neutral
- Stoch D42.25Neutral
- IndicatorValueSignal
- BB Upper1066.22Neutral
- BB Middle992.17Neutral
- BB Lower918.12Neutral
- ATR29.10Low Volatility
- IndicatorValueSignal
- MFI78.55Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 10991.04Bearish
- SMA 20927.62Bullish
- SMA 50826.63Bullish
- EMA 10977.21Bearish
- EMA 20937.47Bullish
- EMA 50846.46Bullish
- DEMA 101011.07Bearish
- DEMA 201009.70Bearish
- DEMA 50968.88Bullish
- TEMA 101002.12Bearish
- TEMA 201020.78Bearish
- TEMA 50N/AN/A
- MACD53.60Bearish
- ADX51.07Strong Trend
- IndicatorValueSignal
- RSI59.59Neutral
- CCI49.19Neutral
- ROC 91.40Bullish
- ROC 1414.12Bullish
- ROC 2516.47Bullish
- Stoch K59.19Neutral
- Stoch D66.00Neutral
- IndicatorValueSignal
- BB Upper1072.02Neutral
- BB Middle927.62Neutral
- BB Lower783.22Neutral
- ATR42.92Low Volatility
- IndicatorValueSignal
- MFI83.87Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 10934.95Bullish
- SMA 20858.37Bullish
- SMA 50719.59Bullish
- SMA 100662.85Bullish
- SMA 200715.80Bullish
- EMA 10945.32Bullish
- EMA 20878.46Bullish
- EMA 50769.21Bullish
- EMA 100721.48Bullish
- EMA 200738.84Bullish
- DEMA 101015.73Bearish
- DEMA 20986.30Bearish
- DEMA 50871.92Bullish
- DEMA 100748.52Bullish
- DEMA 200660.31Bullish
- TEMA 101024.97Bearish
- TEMA 201017.96Bearish
- TEMA 50961.00Bullish
- TEMA 100827.71Bullish
- TEMA 200687.72Bullish
- MACD82.77Bullish
- ADX66.90Strong Trend
- IndicatorValueSignal
- RSI71.53Overbought
- CCI110.78Overbought
- ROC 1425.99Bullish
- ROC 2536.12Bullish
- Stoch K74.17Neutral
- Stoch D81.80Overbought
- IndicatorValueSignal
- BB Upper1060.11Neutral
- BB Middle858.37Neutral
- BB Lower656.63Neutral
- ATR52.32Low Volatility
- IndicatorValueSignal
- MFI88.04Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 20644.56Bullish
- SMA 50714.76Bullish
- EMA 20700.19Bullish
- EMA 50743.16Bullish
- DEMA 20717.12Bullish
- DEMA 50638.08Bullish
- TEMA 20781.02Bullish
- TEMA 50620.21Bullish
- MACD24.28Bullish
- ADX29.99Strong Trend
- IndicatorValueSignal
- RSI62.40Neutral
- CCI166.13Overbought
- ROC 1480.34Bullish
- ROC 2516.52Bullish
- Stoch K93.91Overbought
- Stoch D90.93Overbought
- IndicatorValueSignal
- BB Upper870.42Overbought
- BB Middle644.56Neutral
- BB Lower418.70Neutral
- ATR72.33High Volatility
- IndicatorValueSignal
- MFI82.82Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 6663.08Bullish
- SMA 12702.40Bullish
- SMA 24974.02Bearish
- EMA 6685.40Bullish
- EMA 12736.66Bullish
- EMA 24805.66Bearish
- DEMA 6665.56Bullish
- DEMA 12631.10Bullish
- DEMA 24766.63Bullish
- TEMA 6705.43Bullish
- TEMA 12605.46Bullish
- TEMA 24N/AN/A
- MACD43.17Bearish
- ADX20.11Weak Trend
- IndicatorValueSignal
- RSI51.98Neutral
- CCI-0.75Neutral
- ROC 25-26.53Bearish
- ROC 50177.88Bullish
- Stoch K11.87Oversold
- Stoch D39.55Neutral
- IndicatorValueSignal
- BB Upper1627.37Neutral
- BB Middle897.50Neutral
- BB Lower167.63Neutral
- ATR195.72High Volatility
- IndicatorValueSignal
- MFI48.34Neutral